Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - Successful treatment and prevention of TLS with low-dose rasburicase

European Journal of Haematology

Volumn 75, Issue 6, 2005, Pages 518-521

  Hummel, Margit ^a   Buchheidt, Dieter ^a   Reiter, Sebastian ^a   Bergmann, Jörg ^a   Adam, Katja ^a   Hehlmann, Rüdiger ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic lymphocytic leukemia; Hyperuricemia; Rasburicase; Renal failure; Tumor lysis syndrome; Urate oxidase

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; BICARBONATE; CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CHLORAMBUCIL; CREATININE; CYCLOPHOSPHAMIDE; FLUDARABINE; INFUSION FLUID; INTERLEUKIN 2 RECEPTOR ALPHA; LACTATE DEHYDROGENASE; NITROGEN; PHOSPHATE; PREDNISONE; RASBURICASE; URATE; URATE OXIDASE; UREA;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CREATININE BLOOD LEVEL; DNA MODIFICATION; FLUID THERAPY; HUMAN; IMMUNOPHENOTYPING; LEUKOPENIA; LOW DRUG DOSE; LYMPHADENOPATHY; MALE; OLIGURIA; PRIORITY JOURNAL; PROPHYLAXIS; SACCHAROMYCES CEREVISIAE; TUMOR LYSIS SYNDROME; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CREATININE; CYCLOPHOSPHAMIDE; HUMANS; KIDNEY FAILURE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; RECOMBINANT PROTEINS; TUMOR LYSIS SYNDROME; URATE OXIDASE; URIC ACID; VIDARABINE;

EID: 28044443646     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00550.x     Document Type: Article

References (22)

1. LINCK D, BASARA N, TRAN V, VUCINIC V, HERMANN S, HOELZER D, FAUSER AA. Peracute onset of severe tumor lysis syndrome immediately after 4 Gy fractionated TBI as part of reduced intensity preparative regimen in a patient with T-ALL with high tumor burden. Bone Marrow Transplant 2003;31:935-937.
2. NAVOLANIC PM, PUI CH, LARSON RA, et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia 2003;17:499-514.
3. DANN EJ, GILLIS S, POLLIACK A, OKON E, RUND D, RACHMILEWITZ EA. Brief report: tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia. N Engl J Med 1993;329:1547-1548.
4. TRENDLE MC, TEFFERI A. Tumor lysis syndrome after treatment of chronic lymphocytic leukemia with cladribine. N Engl J Med 1994;330:1090.
5. CHESON BD, FRAME JN, VENA D, QUASHU N, SORENSEN JM. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 1998;16:2313-2320.
6. HUSSAIN K, MAZZA JJ, CLOUSE LH. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature. Am J Hematol 2003;72:212-215.
7. JENSEN M, WINKLER U, MANZKE O, DIEHL V, ENGERT A. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998;77:89-91.
8. YANG H, ROSOVE MH, FIGLIN RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999;62:247-250.
9. VAISBAN E, ZAINA A, BRAESTER A, MANASTER J, HORN Y. Acute tumor lysis syndrome induced by high-dose corticosteroids in a patient with chronic lymphatic leukemia. Ann Hematol 2001;80:314-315.
10. AIVADO M, SCHULTE K, HENZE L, BURGER J, FINKE J, HAAS R. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002;29:19-22.
11. BAND PR, SILVERBERG DS, HENDERSON JF, ULAN RA, WENSEL RH, BANERJEE TK, LITTLE AS. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970;283:354-357.
12. ABLIN A, STEPHENS BG, HIRATA T, WILSON K, WILLIAMS HE. Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Metabolism 1972;21:771-778.
13. HANDE KR, HIXSON CV, CHABNER BA. Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Res 1981;41:2273-2279.
14. MAHMOUD HH, LEVERGER G, PATTE C, HARVEY E, LASCOMBES F. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer 1998;77(Suppl. 4):18-20.
15. PUI CH, MAHMOUD HH, WILEY JM, WOODS GM, LEVERGER G, CAMITTA B, HASTINGS C, BLANEY SM, RELLING MV, REAMAN GH. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19:697-704.
16. JEHA S, KANTARJIAN H, IRWIN D, SHEN V, SHENOY S, BLANEY S, CAMITTA B, PUI CH. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005;19:34-38.
17. BOSLY A, SONET A, PINKERTON CR, MCCOWAGE G, BRON D, SANZ MA, van DEN BH. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003;98:1048-1054.
18. GOLDMAN SC, HOLCENBERG JS, FINKLESTEIN JZ, HUTCHINSON R, KREISSMAN S, JOHNSON FL, TOU C, HARVEY E, MORRIS E, CAIRO MS. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97:2998-3003.
19. HUMMEL M, BUCHHEIDT D, REITER S, BERGMANN J, HOFHEINZ R, HEHLMANN R. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 2003;17:2542-2544.
20. CAIRO MS, BISHOP M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3-11.
21. LEE AC, LI CH, SO KT, CHAN R. Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003;37:1614-1617.
22. COIFFIER B, MOUNIER N, BOLOGNA S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003;21:4402-4406.